Ganga Pharmaceuticals Ltd.
Snapshot View

6.00 ▼0%

05 July 2021, 04:00:00 P.M.

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.ayurvedganga.com
Financial Indicators
Market Cap 2.44 Cr.
Earnings per share (EPS) 0.05 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 121.85 Trailing Twelve Months Ending 2021-03
Industry PE 35.25 Trailing Twelve Months Ending 2021-03
Book Value / Share 13.18 Trailing Twelve Months Ending 2021-03
Price to Book Value 0.46 Calculated using Price: 6.00
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 0.41 Cr. 4,061,500 Shares
FaceValue 10
Company Profile

The company was originally incorporated in Mumbai as “Ganga Pharmaceuticals Private Limited” on September 11, 1989 under the provisions of the Companies Act, 1956 vide certificate of incorporation issued by the Registrar of Companies, Mumbai (the RoC). The company was converted in to a Public Limited Company and consequently the name was changed to “Ganga Pharmaceuticals Limited” vide fresh certificate of incorporation dated September 19, 1994 issued by the RoC, Mumbai.

The company was established as a producer of quality Bulk Ayurvedic Medicines in Mumbai. Apart from manufacturing, the company is also into marketing, distribution of Bulk Ayurvedic Medicines. Under the Management of Late Shri Brijmohan Sharma, the company had created an exceptional market reputation not only in Mumbai but all over Maharashtra. Initially, the company was manufacturing the proprietary products like Ampachan Vati, Khadira Vati and Nirmalaya churna.

Bearing in mind, the growing demand for the above products and newer products, increasing market share in Bulk Ayurvedic Medicine Sector and need for expertise in the business; Bharat Brijmohan Sharma, son of Late Shri Brijmohan Sharma took over the business. Being a Bachelor of Pharmacy from Pune University and a technocrat having rich experience in production and management of Ayurvedic unit, he not only extended the business to the neighbouring states but also introduced newer products within the company. As on date the company, it has 230 number of products in its total portfolio. These products can be divided into two broad categories; Liquid Dosage Form including Oil-based products and Solid Dosage Form including Powder-based products; Tablets and Pills.

Business area of the company

The company is a producer of quality bulk ayurvedic medicines in Mumbai. Apart from manufacturing, the company is also into marketing, distribution of Bulk Ayurvedic Medicines. Its product includes Ampachan Vati; Khadira Vati; Nirmalaya churna etc.  Its products are available in liquid dosage form and solid dosage forms.

Key Events and Milestones

  • 1993: Expanded the product portfolio to the current portfolio in 20 years.
  • 1993: Obtained Import-Export License.
  • 2000: Created and Developed Ayurvedic Pharmacopeias- a in-house guideline to be followed from manufacturing stage to packaging stage.
  • 2000: Set up full fledge in-house Laboratory with the Manufacturing Unit.
  • 2001: Received Good Manufacturing Practice (GMP) Certificate from FDA, Maharashtra.
  • 2004: Established C & F depots in West Bengal & Orissa.
  • 2009: ‘High Performance Capability and Moderate Financial Strength’ Certificate received from NSICCRISIL (valid till 15-12-2010).

 

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
1 Week
1 Month
-20.0%
3 Month
-20.0%
6 Month
-34.07%
1 Year
-14.89%
2 Year
5 Year
-31.03%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 0.88 1.11 1.16 1.28 1.36 1.57 1.91 3.70 3.59
Return on Capital Employed (%) 7.99 8.02 7.68 8.03 6.88 6.15 5.83 7.26 7.18
Return on Assets (%) 0.43 0.57 0.61 0.64 0.77 0.99 1.19 2.34 2.46

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 2 3 3 3 5 5 5 5 5
Non Curr. Liab. 2 2 1 2 1 1 1 1 1
Curr. Liab. 1 1 1 1 1 2 2 2 2
Minority Int.
Equity & Liab. 4 5 5 5 7 8 8 8 8
Non Curr. Assets 2 3 3 3 3 3 4 3 3
Curr. Assets 2 2 2 2 5 4 5 4 4
Misc. Exp. not W/O 0
Total Assets 4 5 5 5 7 8 8 8 8

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 2 2 3 3 3 3 3 3 3
Other Income 0 0 0 0 0 0 0 0 0
Total Income 2 2 3 3 3 3 3 4 3
Total Expenditure -2 -2 -2 -2 -2 -3 -3 -3 -3
PBIDT 0 0 0 0 0 0 0 1 1
Interest 0 0 0 0 0 0 0 0 0
Depreciation 0 0 0 0 0 0 0 0 0
Taxation 0 0 0 0 0 0 0 0 0
Exceptional Items
PAT 0 0 0 0 0 0 0 0 0

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 0 0 0 0 -1 0 0 0 0
Cash Fr. Inv. 0 0 0 0 -1 1 0 0 0
Cash Fr. Finan. 0 0 0 0 2 0 0 0 0
Net Change 0 0 0 0 0 0 0 0 0
Cash & Cash Eqvt 0 0 0 0 0 1 0 0 0

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 66.71 66.71 66.71 66.71 66.71 66.71 66.71 66.71 66.71
Public 33.29 33.29 33.29 33.29 33.29 33.29 33.29 33.29 33.29
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Thu, 08 Jul 2021
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Compliance- Certificate under Reg. 74(5) of SEBI (DP) Regulations 2021
Thu, 08 Jul 2021
Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
0000
Name of the Signatory :- Priti Bhaiya
Designation :- Company Secretary and Compliance Officer
Thu, 08 Jul 2021
Shareholding for the Period Ended June 30 2021
Ganga Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here

Technical Scans View Details

No Scans Found

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 168,769.22 703.40 +1.4%
Divi's Laboratories Ltd. 130,349.05 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. 90,021.63 5,411.25 -0.2%
Cipla Ltd. 76,675.40 950.55 +0.3%
Cadila Healthcare Ltd. 61,992.73 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. 58,965.37 4,100.95 +4.7%
Aurobindo Pharma Ltd. 55,837.02 952.95 -1.1%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 58.12 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 65.69 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 46.13 5,411.25 -0.2%
Cipla Ltd. Consolidated 2021-03 31.88 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 29.06 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 392.16 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.47 952.95 -1.1%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.63 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 14.02 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 5.14 5,411.25 -0.2%
Cipla Ltd. Consolidated 2021-03 4.18 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 4.77 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.83 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.55 952.95 -1.1%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 0.18 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 952.95 -1.1%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 10.09 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 952.95 -1.1%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 12.53 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 952.95 -1.1%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 17,131.99 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 952.95 -1.1%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 1,546.98 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 952.95 -1.1%